TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
TherapeuticsMD, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.86−0.04 (-2.11%)
Close on Oct 19, 2026
- Market cap
- $21.66M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.61 (+48.80%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
TherapeuticsMD, Inc. grew revenue 27.8% to $3.27M over the twelve months to Jun 30, 2026.
Revenue
$3.27M
+27.8% vs. a year earlier
Operating income
-$3.95M
TTM Q2 2026
EPS, diluted
-$0.02
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $21.66M
- P/E ratio
- –
- Price to sales
- 6.62
- Price to book
- 0.80
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.27M
- Net income
- -$217.00K
- EPS, diluted
- -$0.02
- Book value per share
- $2.33
- Diluted shares
- 12M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.27M+27.8% YoY
Gross profit
–
Operating income
-$3.95M
Net income
-$217.00K
EPS, diluted
-$0.02
Free cash flow
–
Reported periodTrailing twelve months